MedTrace Logo

Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19

NCT05122234 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-11-16

No results posted yet for this study

Summary

This study is a multi-centre randomized controlled trial involving severe covid-19 patients. The intervention group will receive mesenchymal stem cell secretomes and standard covid-19 therapy, while the control group receive placebo and standard covid-19 therapy. Clinical presentation, inflamatory marker, laboratory and radiological parameters, RT-PCR conversion, safety profile, and mortality rate will be monitored for a maximum of 14 days after intervention.

Conditions

Interventions

BIOLOGICAL

Injection of secretome - mesenchymal stem cell

Secretome will be given once at a dose of 15 ml per administration dissolved in 100 ml of normal saline. The administration is done intravenously for 60 minutes.

OTHER

Placebo

Normal saline

DRUG

Standard treatment of Covid-19

Standard treatment of Covid-19 based on national protocol.

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Murdani Abdullah, Prof. M.D., PhD, FACG, FASGE · Departemen of Internal Medicine, Faculty of Medicine, University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-10
Primary Completion
2021-07-30
Completion
2021-11-14

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122234 on ClinicalTrials.gov